PGR and neoplasm: Most somatic TP53 mutations occur in patients with the triple negative (TN) or human epithelial growth factor receptor 2 (HER2) subtypes (TN: tumors without expression of the estrogen and progesterone receptors and lacking overexpression of HER2 (ErbB2); HER2: tumor with overexpression of HER2 [16].